TS-075260 — Problem Type 2 diabetes and related metabolic disorders affect hundreds of millions of patients and are frequently accompanied by chronic inflammation, which accelerates disease progression and complications. Existing antidiabetic therapies often fail to adequately address inflammatory pathways and…

TS-075258 — PROBLEM Chronic heart failure following myocardial infarction (MI) afflicts ~6.7 million US adults and is driven by maladaptive immune activation, particularly persistent activation and proliferation of CD4+ T cells. Existing anti-inflammatory and immunomodulatory approaches have largely failed to …

TS-075247 — PROBLEM Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiple organ damage, affecting women at a 9:1 rate as compared to men. The etiology of SLE is complex and incompletely understood; however, the susceptibility of women during the years in which estrogen levels ar…

TS-075237 — Problem The loss or mutation of serine/threonine kinase 11 (STK11), observed in 20–25% of non-small cell lung cancer (NSCLC) cases, is associated with poor prognosis and resistance to immune checkpoint blockade (ICB). While STK11 alterations are commonly linked to immunotherapy resistance, so…

TS-075175 — Problem Idiopathic pulmonary fibrosis (IPF) is a chronic disease where activated fibroblasts mediate the abnormal accumulation of extracellular matrix (ECM) in the lung interstitial space, leading to progressive impairment of pulmonary function. Current IPF therapies are associated with significant…

TS-075161 — Problem Acute and chronic pulmonary inflammation conditions, such as acute respiratory distress syndrome (ARDS), acute lung injury (ALI) and asthma, remain a significant healthcare challenge with high mortality rates, long-term morbidity and a substantial economic burden due to prolonged hospital s…

TS-075141 — THE PROBLEM Current MS treatments typically employ broad immunosuppression rather than targeting specific pathways, resulting in significant side effects and inadequate responses in many patients. The IL-6/STAT3 pathway is critical for balancing inflammatory T effector cells and protective regulato…

TS-065154 — , 2018-345 Revolutionary treatment for ARDS using novel extracellular vesicles loaded with Anti-Inflammatory Agents.

TS-064248 — The Notch signaling pathway is important in immune cell differentiation and maturation. As a result, it has been shown that Notch receptor signaling can promote or suppress adaptive immune responses depending on the particular ligands and receptors involved. A set of native protein-inspired biolog…

TS-057777 — A novel orally-active drug molecule that can inhibit pathological CD4+ T-cells at clinically translatable doses and, blunts progressive cardiac dysfunction and left-ventricular (LV) remodeling during Heart Failure (HF).

TS-057739 — CRISPR/Cas 9 mediated targeting of MIR155HG in primary human T cells creates genomic deletions that disrupt transcription of mature microRNA-155 (miR-155, a miR associated with inflammation). Applying this treatment to donor T cells prior to allogenic hematopoietic stem cell transplantation (allo-HSCT) when treating hematological malignancies and other primary bone marrow disorders can prevent the development of aGVHD in patients.

TS-050220 — Novel natural products and derivatives thereof that exhibit potent in vitro and in vivo activity

TS-040132 — A questionnaire used to understand a patient’s comprehension of their personalized medication plan and the disease fluctuation of systemic lupus erythematous (SLE).

TS-038701 — Modality: Small-molecule prodrug that targets the IL-6/STAT3 signaling pathway Stage of Development: Extensive in vitro and in vivo efficacy (3 MS models, incl. relapsing-remitting EAE); preliminary safety Patent Status: Pat. no. 11,420,946 (US); appl. 17/821,286 (US); appl. 18860926.7 (EP); app…

TS-037260 — A cocktail of locked nucleic acids inhibits the inflammatory response in a humanized murine model of lupus.

TS-036778 — Infectious diseases present a problem for treatment, with concerns for the overuse of antibiotic medicine, inefficiency of modern medicines, and a need in the market for novel technologies that will target and work in conjunction with the host immune system, rather than depending on external mecha…

TS-036760 — Immunomodulating agents have been engineered from Notch receptor ligand extracelluar domains. These are useful for stimulating the immune system.

TS-015239 — Enhancing the mucosal (IgA) immune response by transiently blocking a specific cellular subset during vaccination.

TS-015086 — Estrogen Receptor Beta Agonists for the treatment of breast, colon, and prostate cancers as well as inflammatory diseases.